DaehanPharmaceutical Q3 profit from the main business KRW 8.2 billion, down 23.0% from a year earlier
AI summary · Not investment advice
Daehan Pharm sold KRW 57.0 billion in Q3 and earned KRW 8.2 billion from its main business, down 23.0% from a year earlier and up 1.4% from the prior quarter.
Operating profit · 3 months
KRW 8.2 billion
Key facts
- Revenue (3 months)
- KRW 57.0 billion
- Net income (3 months)
- KRW 5.6 billion
- Period
- Q3 (cumulative 2026.01.01 ~ 2026.09.30)
- Revenue (prior-year 3 months)
- KRW 56.2 billion
- Revenue (year to date)
- KRW 166.3 billion
- Operating profit (prior-year 3 months)
- KRW 10.6 billion
- Operating profit (year to date)
- KRW 24.1 billion
- Net income (prior-year 3 months)
- KRW 8.7 billion
- Net income (year to date)
- KRW 19.4 billion
Commentary
AI commentary · Not investment advice
What happened
Daehan Pharm reported its third-quarter 2026 results (July to September) on a standalone basis. Sales for the quarter were KRW 57.03 billion. That is 1.5% higher than the same 3 months a year earlier (KRW 56.17 billion) and 0.7% higher than the previous quarter.
In the company's terms
Operating profit (profit from the core business) for the quarter was KRW 8.19 billion. It fell 23.0% from the same 3 months a year earlier (KRW 10.64 billion) and rose 1.4% from the previous quarter. Net income (the final profit after taxes and other costs) was KRW 5.65 billion. It fell 35.2% from a year earlier (KRW 8.72 billion) and fell 16.3% from the previous quarter.
What changes for shareholders
For the year to date (January 1 to September 30), sales were KRW 166.35 billion. Operating profit was KRW 24.13 billion and net income was KRW 19.38 billion.
Comments
No comments yet
Comments from shareholders will appear here.
Ad
Verify your holdings and catch the next disclosure
Verify the stocks you hold and get new disclosures as app alerts.

App design sample
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist
D